Biblio Discovery — Demo Discovery Service

36 results for "Mark M. Awad"

Showing 1–20 · 0.51 seconds · RSS

  1. Journal Article

    Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials

    Kruti B. Vora; Biagio Ricciuti; Mark M. Awad

    Scientific Reports, Vol. 11 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people living with human immunodeficiency virus (PLWH), however this high-cancer-risk population has often been excluded from groundbreaking…

  2. Journal Article

    Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

    Mizuki Nishino; Tomoyuki Hida; Sasha Kravets et al.

    European Journal of Radiology Open, Vol. 7 · 2020 · English · DOAJ Scopus

    Purpose: The purpose of the study is to investigate volumetric tumor burden dynamics and tumor growth rates in ALK-rearranged advanced NSCLC patients during crizotinib monotherapy. Methods: The study included 44 ALK-rearranged advanced NSCLC patients treated with crizotinib monotherapy as their…

  3. Journal Article

    Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

    F. Stephen Hodi; Pasi A. Janne; Mark M. Awad et al.

    Journal for ImmunoTherapy of Cancer, Vol. 4 No. 1 · 2016 · English · DOAJ Scopus

    Background Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the…

  4. Journal Article

    Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

    Biagio Ricciuti; Sasha Kravets; Suzanne E. Dahlberg et al.

    Journal for ImmunoTherapy of Cancer, Vol. 7 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with…

  5. Journal Article

    Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

    Mark M. Awad; Yvan Le Bruchec; Brian Lu et al.

    Frontiers in Oncology, Vol. 11 · 2021 · English · DOAJ Scopus

    BackgroundHistone deacetylase (HDAC) overexpression has been documented in various cancers and may be associated with worse outcomes. Data from early-phase studies of advanced non-small cell lung cancer (NSCLC) suggest encouraging antitumor activity with the combination of an HDAC inhibitor and…

  6. Journal Article

    Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer

    Mizuki Nishino; Biagio Ricciuti; Joao V Alessi et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 12 · 2025 · English · DOAJ Scopus

    Background Despite immunotherapy±chemotherapy has transformed the therapeutic landscape for patients with non-small cell lung cancer (NSCLC), critical questions remain regarding how detailed smoking history affects the evolving treatment options and the underlying molecular mechanisms driving these…

  7. Journal Article

    Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

    Mariano Severgnini; Biagio Ricciuti; Alissa Keegan et al.

    Journal for ImmunoTherapy of Cancer, Vol. 8 No. 2 · 2020 · English · DOAJ Scopus

    Background Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors would correlate with clinical responses. New…

  8. Journal Article

    Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers

    Taek-Chin Cheong; Ahram Jang; Qi Wang et al.

    Nature Communications, Vol. 15 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions are followed typical recurrent patterns, but the underlying mechanisms and clinical implications of…

  9. Journal Article

    Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer

    Xinan Wang; Kangcheng Hou; Biagio Ricciuti et al.

    HGG Advances, Vol. 5 No. 3 · 2024 · English · DOAJ Scopus

    Summary: The KRAS mutation is the most common oncogenic driver in patients with non-small cell lung cancer (NSCLC). However, a detailed understanding of how self-reported race and/or ethnicity (SIRE), genetically inferred ancestry (GIA), and their interaction affect KRAS mutation is largely…

  10. Journal Article

    Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology

    Elio Adib; Amin H. Nassar; Sarah Abou Alaiwi et al.

    Genome Medicine, Vol. 14 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background Genomic alterations in 8 genes are now the targets of FDA-approved therapeutics in non-small cell lung cancer (NSCLC), but their distribution according to genetic ancestry, sex, histology, and smoking is not well established. Methods Using multi-institutional genetic testing…

  11. Journal Article

    Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy

    Muhammad Mohsin Fareed; Luke R. G. Pike; Andrew Bang et al.

    Frontiers in Oncology, Vol. 9 · 2019 · English · DOAJ Scopus

    Background: There is increasing use of immune checkpoint blockade (ICB) across multiple cancer types, including in patients at risk for vertebral metastases and cord compression. These patients are often treated with palliative radiotherapy (PRT); however, data evaluating the combination of PRT and…

  12. Journal Article

    Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer

    Daniel Reinhorn, MD; Jonathan Kuten, MD, MHA; Isabel Preeshagul, DO, MBS et al.

    JTO Clinical and Research Reports, Vol. 7 No. 7 · 2026 · English · DOAJ Scopus

    Background: Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are HER2-targeting antibody-drug conjugates (ADCs) with activity in HER2-mutant non-small cell lung cancer (NSCLC). Whether patients benefit from sequential HER2-directed ADCs therapy remains unknown. Methods: We conducted…

  13. Journal Article

    Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancer

    Katharina V. Hoebel; James R. Lindsay; Jennifer Altreuter et al.

    npj Precision Oncology, Vol. 10 No. 1 · 2026 · English · DOAJ Scopus

    Abstract The spatial organization of immune and tumor cells within the tumor microenvironment (TME) has a critical influence on antitumor immunity and patient survival. However, hand-engineered metrics such as cell densities or pairwise proximity scores fail to capture the complexity of local…

  14. Journal Article

    Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

    Patrick M. Forde; Jonathan Spicer; Shun Lu et al.

    New England Journal of Medicine · 2022 · French · OpenAlex Scopus

    BACKGROUND: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm…